H3-DYNAMICS
16.1.2023 16:08:41 CET | Business Wire | Press release
H3 Dynamics and Hylium Industries have joined forces to boost the performance of zero emission hydrogen-electric flight, by combining the strengths of Hylium’s liquid hydrogen storage and liquification solutions, and H3 Dynamics’ distributed hydrogen-electric propulsion nacelles, ultra-light fuel cells, and new hydrogen drone refueling stations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230116005162/en/
Joint development for transatlantic crossing with ISAE-SUPAERO Toulouse, H3 Dynamics - using HYLIUM Liquid hydrogen storage (Photo: Business Wire)
Moving to liquid hydrogen represents a significant capability leap for small electric-powered unmanned systems. Cryogenic (liquid) hydrogen stores 3 times more energy as compressed gas in the same given volume. This means delivery drones will be able to fly further, mapping and ISR missions could be done on a much bigger scale.
To illustrate the jump in performance, the same 25kg hydrogen-electric propulsion UAV demonstrated by H3 Dynamics last July in France, will be able to fly over 900km with a single fill. With pressurized hydrogen, that range reduces to 400km, which is still 3 times more than a battery-powered equivalent.
“When combined, our global best-in-class solutions achieve the global performance limit for low-altitude electric powered flight” says Taras Wankewycz, CEO H3 Dynamics. “We are proud to be working with Hylium to move hydrogen-electric flight propulsion to the next level”
Now all the various forms of hydogen drones and UAVs powered by H3 Dynamics including hydrogen airships, multi-rotors, vertical take-off and landing (VTOL), have a way to further boost flight durations by another factor of 3 over pressurized hydrogen systems, or a factor of 10 compared to batteries.
H3 Dynamics also recently announced a first hydrogen production, and automated hydrogen refueling mobile station for hydrogen UAV operations. Named H2FIELD the mobile station produces hydrogen from water and delivers compressed hydrogen gas tanks to the operator with little human intervention and no required hydrogen expertise. H3 Dynamics and Hylium’s partnership will upgrade the station so that it can fill liquid hydrogen tanks.
Developed in South Korea, Hylium’s breakthrough technology provides one of the most advanced solutions and has already been proven in a number of applications. South Korea is also leading the development for LH2 standardisation. One local proposal was accepted as a draft standard by a global ISO committee.
Hylium and H3 Dynamics technologies are currently being integrated to attempt a 3,300km crossing of the South Atlantic, in a program led by ISAE SUPAERO Toulouse, one of the world’s leading aerospace engineering schools. H3 Dynamics’ team developed a special fuselage design that can store a small LH2 tank and manage the thermal behavior of all the propulsion sub-systems.
LH2 technology will also be a next step in H3 Dynamics’ hydrogen-electric propulsor nacelles roadmap. A first twin engine cargo drone powered by these self-contained nacelles took off in the sky of Paris during the summer 2022, using 2 compressed hydrogen tanks – one in each nacelle. The goal now will be to switch them out for liquid hydrogen tanks with a lighter construction and a higher fuel capacity.
About H3 Dynamics www.h3dynamics.com
H3 Dynamics is on a mission to decarbonize aviation with a unique technology solution around distributed hydrogen-electric propulsion, as well as hydrogen refueling and airport power solutions. The company has created a unique pathway to de-risk long term hydrogen aviation developments by starting commercially now with small, scalable solutions. H3 Dynamics employs 93 team members from its 3 regional headquarters in Toulouse, Austin and Singapore. It is a member of the Alliance for Zero Emission Aviation under the European Commission, Sustainable Aero Lab, the Lufthansa Cleantech Hub, the Paris Advanced Air Mobility Alliance, and Aerospace Valley in Toulouse.
About Hylium Industries: http://hylium-industries.com/
HYLIUM INDUSTRIES, INC. was established in 2014 as a Korea Institute of Science and Technology (KIST) venture company. Since then Hylium have been developing the Korea’s first cryogenic liquid hydrogen manufacturing and storage technologies with R&D support from the Korean Government.
Hylium has developed various technologies related to the hydrogen liquefaction system and owns over 20 patents and intellectual property rights, with more patents pending. In 2015 Hylium Industries’ technologies were acknowledged by the Cryogenic Engineering Conference with a Russel B. Scott Memorial Award for the Best Application in Small-Capacity Hydrogen Liquefaction Technology.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230116005162/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom